Published on: 15 July 2013
Skip to main content
In a Commentary in the latest issue of JITC, members of the SITC Executive Committee and JITC Section Editor Dr. Leisha A. Emens examine the need for finding an appropriate balance between the rapid development of promising cancer immunotherapeutics through clinical trials and ensuring patient safety through appropriate and scalable trial design.
Grover’s-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy
Viktor H. Koelzer, et al
CLINICAL TRIALS MONITOR
PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?
Claud Grigg and Naiyer A. Rizvi
Circulating protein and antibody biomarker for personalized cancer immunotherapy
It’s TIME for a biomarker-driven approach to cancer immunotherapy
Leisha A. Emens
Phase II study of vemurafenib followed by ipilimumab...
Asim Amin, et al
A hypofractionated radiation regimen avoids the lymphopenia associated with neoadjuvant chemoradiation therapy...
Todd Crocenzi, et al
Adenosine-generating ovarian cancer cells attract myeloid cells which differentiate into adenosine-generating tumor...
Itsaso Montalbán del Barrio, et al
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy
Lucie Heinzerling, et al
View and search for all articles in the journal here.
Published on: 15 July 2013
Published on: 29 July 2013
Published on: 27 August 2013
Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.
JITC welcomes submissions to the following sections:
In this “Glimpse into the Future”, entitled Harnessing autophagy to promote anti-tumor Immunity with the DRibbles vaccine, David Page et al. describe the pre-clinical rationale, translational data, and early clinical data pertaining to the DRibbles vaccine. This novel vaccine is produced by manipulating autophagy and could induce tumor-specific immune responses against a variety of conventional tumor-associated antigens.
Written by the members of the SITC Immune Biomarkers Task Force, these brief primers highlight important aspects of both standardized and novel technologies available in clinical trial settings.
Read all of the articles here.
As a way to say thank you to the dedicated Society for Immunotherapy of Cancer (SITC) members who tirelessly work to advance the science and ultimately to improve the lives of patients with cancer, the Society is pleased to offer its members waived article processing charges for manuscripts published in JITC.
Two $1,000 USD awards will be given for the JITC Best Clinical/Translational Paper and the JITC Best Basic Science Paper published in JITC.
The Society for Immunotherapy of Cancer (SITC) is a 501 (c)(3) non-profit society of medical professionals that was established in 1984 to exchange, encourage and promote information about the promise and breakthroughs of biological therapies, including immunotherapy, for patients with cancer. SITC is the world's leading member-driven society of medical professionals dedicated to advancing cancer immunotherapy through its initiatives, educational sessions, and collaborative endeavors. The Society has become the forum for innovative discussions in the field.
Society members include nearly 1000 influential leaders and scientists engaged in tumor immunology and cancer immunotherapy, including academicians, senior researchers, clinicians, students, government representatives, and industry leaders from around the world. SITC's members represent 17 medical specialties and are engaged in research and treatment of at least a dozen types of cancer.
It is the mission of the Society for Immunotherapy of Cancer to improve cancer patient outcomes by advancing the science, development and application of immunotherapy through our core values of interaction/integration, innovation, translation and leadership in the field. SITC aims to make cancer immunotherapy a standard of care and the word “cure” a reality for cancer patients everywhere.